Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates
of different solutions subcutaneously (SC) infused and preceded by human recombinant
hyaluronidase (hylenex) 150 units.
In Stage 1, the comparison will be Normal Saline (NS) solution to Lactated Ringer's (LR)
solution. Each subject will receive 500 milliliters (mL) of solution, consisting of NS in
one thigh and LR in the other thigh. Immediately prior to the infusions, each thigh will
have 150 units of hylenex.
In Stage 2, the comparison will be NS solution and buffered NS solution.
This Phase IV, randomized, double-blinded study in volunteer subjects to evaluate the
tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and
preceded by human recombinant hyaluronidase (hylenex) 150 units. The study will be
conducted in two sequential stages.
In Stage 1, the comparison will be NS solution to LR solution. Each subject will receive
simultaneous SC infusions of 500 mL (from a 500 mL bag) of solution in each anterior thigh,
consisting of NS in one thigh and LR in the other thigh. The thighs (left vs. right) to
receive NS and LR will be randomized and double blinded. Immediately prior to the
infusions, each thigh will have 150 units of hylenex simultaneously injected.
Tolerability will be assessed based on the subject's self-assessment of discomfort on a
visual analog scale (VAS). Safety will be assessed by physical examination targeted at
infusion sites, vital signs, and adverse events. The amount of fluid infused will be
assessed by weighing the infusion bag, fluid and tubing at designated time points, and
allowing the determination of flow rate.
Stage 2 will be conducted only if the observed Stage 1 VAS mean maximum pain score is at
least 25 mm higher for one solution compared to the other. Stage 2 will evaluate the
tolerability, safety, and flow rates of subcutaneously infused NS solution and buffered NS
1. Male or female, 18 to 60 years of age.
2. Intact normal skin without in the areas intended for infusion.
3. No fluid intake for 12 hours prior to the start of the study infusion.
4. Vital signs (Blood Pressure (BP), Heart Rate (HR), Respiratory Rate (RR)) within
5. Metabolic panel within normal range.
6. A negative urine or serum pregnancy test.
7. Signed, written Institutional Review Board (IRB)-approved informed consent.
1. Lower extremity edema.
2. Lower extremity pathology that could interfere with study outcome.
3. Rales on lung auscultation.
4. History of cardiovascular disease.
5. Allergy to hyaluronidase.
6. Allergy to bee or vespid venom.
7. Pregnancy or breast-feeding woman.
8. Use of any investigational drug or device within 30 days of enrollment.